MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Create the #1 medical social network (Video/Pictures)
Global aggregator of choice for advanced medical technology business intelligence
Innovation & Royalty Aggregator
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)*
Organization & Developments: Vertex
Parents
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)*
Children
*Bioassay screens to aid in drug development
*Organization & Developments: Vertex (Archives 2011-2018)
*The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies.
*Vertex has generated the excitement around what could be a first-in-class protease inhibitor drug for hepatitis C (2010)
*Vertex is known for cystic fibrosis drugs like Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio.
*Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases.
*Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
2014: Vertex Pharmaceuticals: A Long-Term Growth Monster
2019: How Vertex delivered on cystic fibrosis
2019: Vertex wins fast approval for cystic fibrosis drug
2019: Vertex: Shareholders Might Have Reason To Breathe More Easily_seekingalpha.com
2019: Vertex's Latest Data May Lead To Expanded Cystic Fibrosis Market_seekingalpha.com
2020: Vertex Pharmaceuticals Is A Cystic Fibrosis Giant, But No. 1 Biotech Stock Makes Bold New Move_www.investors.com
2020: Vertex: Recent Clinical Setback Underscores The Need To Expand The Pipeline
2020: Vertex: The Cheapest And Highest Quality Monopoly In The Market
2021: Vertex Pharmaceuticals Poised For Long-Term Growth
2021: Vertex: Moving Past The Disappointing VX-864 Results
2021: Vertex: While The Market Remains Indifferent, Now Is The Time To Commit
2022; MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program_Biohealth Innovation
2022: CRISPR heads to the FDA_Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022_vrtx
2022: Vertex (VERX) Investor Presentation -Slideshow_ seekingalpha.com
2022: Vertex Pharmaceuticals: A Buy For Growth Potential_ seekingalpha.com
2022: Vertex Pharmaceuticals: Growth Outside Of Cystic Fibrosis Critical For Additional Value Creation_ seekingalpha.com
2022: Vertex: High Growth For Years Ahead_ seekingalpha.com
2022: Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues_ seekingalpha.com
2023: 3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
2023: A Total Return Superstar: Vertex Pharmaceuticals
2023: Crispr Therapeutics: ICER Puzzles The Prospects
2023: FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
2023: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
2023: Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed_ seekingalpha.com
2023: Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
2023: Vertex cell therapy lets patients with type 1 diabetes stop insulin
2023: Vertex Pharmaceuticals Looks Expensive, Though It Isn't_ seekingalpha.com
2023: Vertex Pharmaceuticals: Critical Period For The Pipeline Is Approaching
2023: Vertex wins FDA label expansion for cystic fibrosis therapy Trikafta_ seekingalpha.com
2023: Vertex, CRISPR score landmark FDA approval for sickle cell disease gene therapy Casgevy
2023: Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans (NASDAQ:VRTX)
2023: Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles_ seekingalpha.com
2024: CMS names two drug manufacturers for cell and gene therapy model
2024: Cutting Edge Gene Therapy_ Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy
2024: In Another Win for CRISPR, FDA Approves Casgevy for Beta Thalassemia
2024: Non-opioid drug from Vertex cuts pain in major trial tests
2024: Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies
2024: The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names_ Vertex & Regeneron-surpass-100b-market-caps
2024: The First Crispr Treatment Is Making Its Way to Patients
2024: These microscopic tunnels are a goldmine for new medicines_Ion channel research
2024: This High-Flying Stock Just Got Some Bad News: Should You Sell?
2024: UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
2024: Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range_seekingalpha.com
2024: Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)
2024: Vertex Pharma: Why I Am Buying This Dip
2024: Vertex Pharmaceuticals Incorporated 2023 Q4 - Results - Earnings Call Presentation
2024: Vertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
2024: Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
2024: Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It
2024: Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride
2024: Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'
2024: Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024
2024: Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time_
2024: Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
2025: 5 FDA decisions to watch in the first quarter of 2025
2025: A new, non-opioid pain drug is here. Getting it to patients could be agony.
2025: Cell and Gene Therapy Access Model is excited to announce the 33 states participating ... New CMS Payment Model Launched for Sickle Cell Gene Therapy
2025: FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
2025: Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
2025: Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
2025: Vertex discontinues AAV research for gene therapies
2025: Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
2025: Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
2025: Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating_ seekingalpha.com
2025: Vertex Pharmaceuticals' SWOT analysis: stock outlook mixed as CF leader faces 2025 hurdles
2025: Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
2025: Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?
2025: Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
2025: Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
2025: Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
2025: Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
2025: Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
Jumps
*Key People: Vertex
Finance & Acquisition: Vertex